|
17 Jul 2020 |
Interim Six-Month Data of RPGR Gene Therapy Shows Significant Vision Improvement in Patients Living with X-Linked Retinitis Pigmentosa
|
|
17 Jul 2020 |
European Medicines Agency Validates Bristol Myers Squibb’s Application for CAR T Cell Therapy Lisocabtagene Maraleucel (liso-cel)
|
|
16 Jul 2020 |
Oncorus Initiates First-in-Human Phase 1 Study of ONCR-177 for the Treatment of Adult Subjects with Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors
|
|
16 Jul 2020 |
Oncorus Announces Clinical Trial Collaboration with Merck to Evaluate the Combination of Oncorus’ ONCR-177 with Merck’s KEYTRUDA® (pembrolizumab) in Adult Patients with Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors
|
|
15 Jul 2020 |
RIBOMIC Announces Dosing of First Subject in RBM-007 Phase 1 Clinical Trial for Achondroplasia
|
|
15 Jul 2020 |
Celyad Oncology Announces FDA Clearance of IND Application for CYAD-211, First shRNA-based, Non-Gene Edited Allogeneic CAR T Therapy
|
|
13 Jul 2020 |
Rocket Pharmaceuticals Announces First Patient Treated in Phase 1 Trial of RP-L301 Gene Therapy for Pyruvate Kinase Deficiency
|
|
13 Jul 2020 |
Adverum Biotechnologies Announces First Patient Randomized in Phase 2 INFINITY Trial of ADVM-022 Single Injection Gene Therapy for Diabetic Macular Edema (DME)
|
|
13 Jul 2020 |
Fate Therapeutics Announces FDA Clearance of IND Application for First-ever iPSC-derived CAR T-Cell Therapy
|
|
13 Jul 2020 |
Spark Therapeutics Announces Updated Data on SPK-8011 from Phase 1/2 Clinical Trial in Hemophilia A at ISTH 2020 Virtual Congress
|
|
10 Jul 2020 |
Ziopharm Oncology Announces Initiation of Phase 1 Trial Evaluating Rapid Personalized Manufacturing CAR-T Technology in Patients with Relapsed CD19+ Leukemias and Lymphomas
|
|
09 Jul 2020 |
Precision BioSciences Regains Rights to In Vivo Hepatitis B Virus Program
|
|
08 Jul 2020 |
Kiadis licenses previously undisclosed pre-clinical K-NK-cell programs to Sanofi, with total potential deal value of €875 million, plus royalties
|
|
07 Jul 2020 |
Celixir provides update on ongoing clinical programme with lead therapeutic candidate CLXR-001
|
|
07 Jul 2020 |
Johns Hopkins Reports Promising Clinical Data in COVID-19 ARDS Treated with Cellenkos' Cord Blood T-Regulatory Cells
|
|
07 Jul 2020 |
Cellectis Reports Clinical Hold Placed on MELANI-01 Study
|
|
06 Jul 2020 |
GenSight Biologics Reports Sustained Efficacy and Safety Among LHON Patients Three Years After LUMEVOQ® Treatment
|
|
03 Jul 2020 |
AffyImmune Therapeutics presents novel CAR T development programs at the annual meeting of the American Association of Cancer Research
|
|
02 Jul 2020 |
AltruBio moves forward with clinical development of Neihulizumab in Steroid-Refractory Acute Graft-versus-Host Disease after encouraging Phase 1a results
|
|
02 Jul 2020 |
Xenetic Biosciences, Inc. Provides Development Update for Its Personalized CAR T Platform Technology, XCART(TM)
|
|
01 Jul 2020 |
BioCardia Announces Activation of Pivotal Trial Studying CardiAMP Cell Therapy Trial to Treat Chronic Myocardial Ischemia
|
|
01 Jul 2020 |
Amniox Announces Initiation for First of Two Phase 3 Clinical Trials of Cryopreserved Umbilical Cord TTAX01 Allograft to Treat Complex Wagner Grade 3-4 Diabetic Foot Ulcers
|
|
30 Jun 2020 |
AOBiome Reports Successful Clinical Trials (Phase 2a in Adults and Phase 1b in Pediatrics) in Pruritus (Itch) Associated with Atopic Dermatitis
|
|
29 Jun 2020 |
SFA Therapeutics Announces FDA Approval To Begin IND Trial
|
|
29 Jun 2020 |
PTC Therapeutics Announces CHMP Recommendation of Translarna™ (ataluren) Label Update for Non-Ambulatory Patients with Duchenne Muscular Dystrophy
|
